Inflammatory Bowel Disease

Integrative Medicine, Second Edition

Volumn , Issue , 2007, Pages 541-554

  Galland, Leo ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85158955252     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-2954-0.50053-3     Document Type: Chapter

References (193)

1. DK Podolsky (2002) Inflammatory bowel disease. N Engl J Med 347 417-429.
2. N Darfeuille-Michaud A, Neut C, Barnich, et al. (1998) Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115 1405-1413.
3. A Swidinski, A Vladhoff, A Pernthaler, et al. (2002) Mucosal flares in inflammatory bowel disease. Gastroenterology 122 44-54.
4. TT MacDonald, A DiSabatino and JN Gordon (2005) Immunopathogenesis of Crohn's disease. J PEN 29 S118-S125.
5. IJ Fuss, M Neurath, M Boirivant, et al. (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of interferon gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157 1261-1270.
6. S Dionne, I.D.H.J. D'Agata ID, Hiscott J, et al. (1998) Colonic explant production of IL-1 and its receptor antagonist in imbalanced in inflammatory bowel disease. Clin Exp Immunol 112 381-387.
7. MA Gassull (2003) Nutrition and inflammatory bowel disease: Its relation to pathophysiology, outcome and therapy. Dig Dis 21 220-227.
8. NJ Simmonds and SD Rampton (1993) Inflammatory bowel disease: A radical view. Gut 34 865-868.
9. KP Lih-Brody L, Powell SR, Collier, et al. (1996) Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 41 2078-2086.
10. GD Buffington and WF Doe (1995) Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients. Free Radic Res 22 131-143.
11. R D'Odorico A, Bortolan S, Cardin, et al. (2001) Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol 36 1289-1294.
12. A Ojuawo and L Keith (2002) The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med 48 116-119.
13. KM Hendricks and WA Walker (1988) Zinc deficiency in inflammatory bowel disease. Nutr Rev 46 401-408.
14. LJ Hinks, KD Inwards, B Lloyd and B Clayton (1988) Reduced concentrations of selenium in mild Crohn's disease. J Clin Pathol 41 198-201.
15. BJ Geerling, A Badart-Smook, RW Stockbrugger and RJ Brummer (2000) Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 54 514-521.
16. MA Gassull (2004) Review article: The role of nutrition in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 20(Suppl 4) 79-83.
17. MA Gassull (2003) Nutrition and inflammatory bowel disease: Its relation to pathophysiology, outcome and therapy. Dig Dis 21 220-227.
18. D Hollander, CM Vadherim, A Brettholz, et al. (1986) Increased intestinal permeability in patient's with Crohn's disease and their relatives: A possible etiologic factor. Ann Intern Med 105 883-885.
19. M Peeters, Y Ghoos, B Maes, et al. (1994) Increased permeability of macroscopically normal small bowel in Crohn's disease. Dig Dis Sci 39 2170-2176.
20. RJ Hilsden, J Meddings and LR Sutherland (1995) Aspirin provokes an exaggerated increase in the lactulose-mannitol permeability index in first-degree relatives of Crohn's patients. Gastroenterology 108 A834.
21. J Wyatt, H Vogelsgang, W Hubl, et al. (1993) Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341 1437-1439.
22. TT MacDonald, A DiSabatino and JN Gordon (2005) Immunopathogenesis of Crohn's disease. JPEN J Parenter Enteral Nutr 29 S118-S125.
23. U Pirzer, A Schonhaar, B Fleischer, et al. (1991) Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet 338 1238-1239.
24. AM Griffiths (2005) Enteral nutrition in the management of Crohn's disease. JPEN J Parenter Enteral Nutr 29 S108-S117.
25. X Dray and P Marteau (2005) The use of enteral nutrition in the management of Crohn's disease in adults. JPEN J Parenter Enteral Nutr 29(Suppl) S166-S169.
26. IR Sanderson and NM Croft (2005) The anti-inflammatory effects of enteral nutrition. JPEN J Parenter Enteral Nutr 29(Suppl) S134-S138.
27. P Lionetti, ML Callegari, S Ferrari, et al. (2005) Enteral nutrition and microflora in pediatric Crohn's disease. JPEN J Parenter Enteral Nutr 29(Suppl) S173-S175.
28. S Verma, S Brown, B Kirkwood and MH Giaffer (2000) Polymeric versus elemental diet as primary treatment in active Crohn's disease: A randomized, double-blind trial. Am J Gastroenterol 95 735-739.
29. Zachos M, Tondeur M, Griffiths AM: Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev (3)CD000542, 2001.
30. GR Greenberg, CR Fleming, KN Jeejeebhoy, et al. (1988) Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 29 1309-1315.
31. T Johnson, S Macdonald, SM Hill, et al. (2006) Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: A randomised controlled trial. Gut 55 356-361.
32. F Gonzalez-Huix F, de Leon R, Fernandez-Ban~ares, et al. (1993) Polymeric enteral diets as primary treatment of active Crohn's disease: A prospective steroid-controlled trial. Gut 34 778-782.
33. SJ Middleton, JT Rucker, GA Kirby, et al. (1995) Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease. Clin Nutr 14 229-236.
34. T Bamba, T Shimoyama, M Sasaki, et al. (2003) Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: A randomized, controlled trial. Eur J Gastroenterol Hepatol 15 151-157.
35. T Sakurai, T Matsui, T Yal, et al. (2002) Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: A randomized-controlled trial comparing nutrient formulas. JPEN J Parenter Enteral Nutr 26 98-103.
36. C Knight, W El-Matary, C Spray and BK Sandhu (2005) Long-term outcome of nutritional therapy in paediatric Crohn's disease. Clin Nutr 24 775-779.
37. NA Afzal, S Davies, M Paintin, et al. (2005) Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci 50 1471-1475.
38. H Ikeuchi, T Yamamura, H Nakano, et al. (2004) Efficacy of nutritional therapy for perforating and non-perforating Crohn's disease. Hepatogastroenterology 51 1050-1052.
39. R Nieves and RT Jackson (2004) Specific carbohydrate diet in treatment of inflammatory bowel disease. Tenn Med 97 407.
40. E Gottschall (1994) Breaking the Vicious Cycle Kirkton, Ontario: Kirkton Press
41. T Matsui, I Mitsuo, M Fujishima, et al. (1990) Increased sugar consumption in Japanese patients with Crohn's disease. Gastroenterol Jpn 25 271.
42. GA Martini and JW Brandes (1976) Increased consumption of refined carbohydrates in patients with Crohn's disease. Klin Wochens 54 367-371.
43. JR Thurnton, PM Emmett and KW Heaton (1979) Diet and Crohn's disease: Characteristics of the preillness diet. BMJ 2 762-764.
44. JF Mayberry, J Rhodfes and RC Newcombe (1980) Increased sugar consumption in Crohn's disease. Digestion 20 323-326.
45. KW Heaton, JR Thornton and PM Emmett (1979) Treatment of Crohn's disease with an unrefined-carbohydrate, fiber-rich diet. BMJ 2 764-766.
46. L Galland (1999) Nutritional therapy for Crohn's disease: Disease modifying and medication sparing. Altern Ther 5 94-95.
47. MS Inan, RJ Rasoulpour, L Yin, et al. (2000) The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 118 724-734.
48. P Vernia, V Annese, G Bresci, et al. (2003) Gruppo Italiano per lo Studio del Colon and del Retto, Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: Results of a multicentre trial. Eur J Clin Invest 33 244-248.
49. WE Roediger, A Duncan, O Kapaniris and S Millard (1993) Reducing sulfur compounds of the colon impair colonocyte nutrition: Implications for ulcerative colitis. Gastroenterology 104 802-809.
50. WE Roediger, J Moore and W Babidge (1997) Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci 42 1571-1579.
51. EA Magee, CJ Richardson, R Hughes and JH Cummings (2000) Contribution of dietary protein to sulfide production in the large intestine: An in vitro and a controlled feeding study in humans. Am J Clin Nutr 72 1488-1494.
52. SL Jowett, CJ Seal, MS Pearce, et al. (2004) Influence of dietary factors on the clinical course of ulcerative colitis: A prospective cohort study. Gut 53 1479-1484.
53. WE Roediger (1998) Decreased sulphur aminoacid intake in ulcerative colitis. Lancet 351 1555.
54. M Ballegaard, A Bjergstrom, S Brondum, et al. (1997) Self-reported food intolerance in chronic inflammatory bowel disease. Scand J Gastroenterol 32 569-571.
55. AM Riordan, JO Hunter, RE Cowan, et al. (1993) Treatment of active Crohn's disease by exclusion diet: East Anglican multicentre controlled trial. Lancet 342 1131-1134.
56. E Alun Jones V, Workman and AH Freeman (1985) Crohn's disease: Maintenance of remission by diet. Lancet 2 177-180.
57. RMR Barnes, S Allan, CH Taylor-Robinson, et al. (1990) Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: Is IgA antibody a marker for Crohn's disease? Int Arch Allergy Appl Immunol 92 9-15.
58. A Konrad, C Rutten, B Flogerzi, et al. (2004) Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease. Inflamm Bowel Dis 10 97-105.
59. GR Barclay, H McKenzie, J Pennington, et al. (1992) The effect of dietary yeast on the activity of stable chronic Crohn's disease. Scand J Gastroenterol 27 196-200.
60. SL Jowett, CJ Seal, E Phillips, et al. (2004) Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr 23 161-170.
61. S Canbdy, G Borok, JP Wright, et al. (1995) The value of an elimination diet in the management of patients with ulcerative colitis. S Afr Med J 85 1176-1179.
62. R Wright and SC Truelove (1965) A controlled trial of various diets in ulcerative colitis. BMJ 2 138-141.
63. JB Mason (1989) Folate, colitis, dysplasia, and cancer. Nutr Rev 47 314-317.
64. Y Chowers, BA Sela, R Holland, et al. (2000) Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am J Gastroenterol 95 3498-3502.
65. HJ Den Heijer M, Koster T, Blom, et al. (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334 759-762.
66. BA Lashner, KS Provencher, DL Seidner, et al. (1989) Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis: A case-control study. Gastroenterology 97 255-259.
67. M Diculescu, M Ciocirlan, M Ciocirlan, et al. (2003) Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: The old and new evidence. Rom J Gastroenterol 12 283-286.
68. EC Logan, LM Williamson and DR Ryrie (1986) Sulphasalazine associated pancytopenia may be caused by acute folate deficiency. Gut 27 868-872.
69. WL Beeken (1975) Remediable defects in Crohn disease. Arch Intern Med 135 686-690.
70. J Romagnuolo, RN Fedorak and VC Dias (2001) Hyperhomocysteinemia and inflammatory bowel disease: Prevalence and predictors in a cross-sectional study. Am J Gastroenterol 96 2143-2149.
71. LP Penix (1998) Ischemic strokes secondary to vitamin B-12 deficiency-induced hyperhomocystinemia. Neurology 51 622-624.
72. S Abe, Y Wakabayashi and S Hirose (1989) [Megaloblastic anemia associated with diffuse intestinal Crohn's disease]. Rinsho Ketsueki 30 51-55.
73. S Saibeni, M Cattaneo, M Vecchi, et al. (2003) Low vitamin B-6 plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: Role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 98 112-117.
74. M Younes-Mhenni S, Derex L, Berruyer, et al. (2004) Large-artery stroke in a young patient with Crohn's disease: Role of vitamin B-6 deficiency-induced hyperhomocysteinemia. J Neurol Sci 221 113-115.
75. X Fernandez-Banares F, Abad-Lacruz A, Xiol, et al. (1989) Vitamin status in patients with inflammatory bowel disease. Am J Gastroenterol 84 744-748.
76. E Aghdassi, E Wendland, H Steinhard, et al. (2003) Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress: A randomized controlled trial. Am J Gastroenterol 98 348-353.
77. A Rumi G Jr, Szabo I, Vincze, et al. (2000) Decrease of serum carotenoids in Crohn's disease. J Physiol Paris 94 159-161.
78. A Bousvaros, D Zurakowski, C Duggan, et al. (1998) Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: Effect of disease activity. J Pediatr Gastroenterol Nutr 26 129-135.
79. JM Reimund, Y Arondel, G Escalin, et al. (2005) Immune activation and nutritional status in adult Crohn's disease patients. Dig Liver Dis 37 424-431.
80. GM Sampietro, M Cristaldi, G Cervato, et al. (2002) Oxidative stress, vitamin A and vitamin E behaviour in patients submitted to conservative surgery for complicated Crohn's disease. Dig Liver Dis 34 696-701.
81. I Janczewska, W Bartnik, E Butruk, et al. (1991) Metabolism of vitamin A in inflammatory bowel disease. Hepatogastroenterology 38 391-395.
82. JP Wright, AS Mee, A Parfitt, et al. (1985) Vitamin A therapy in patients with Crohn's disease. Gastroenterology 88 512-514.
83. S Norrby, R Sjodahl and C Tagesson (1985) Ineffectiveness of vitamin A therapy in severe Crohn's disease. Acta Chir Scand 151 465-468.
84. AD Harries, R Brown, RV Heatley, et al. (1985) Vitamin D status in Crohn's disease: Association with nutrition and disease activity. Gut 26 1197-1203.
85. H Vogelsang, P Ferenci, W Woloszczuk, et al. (1989) Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci 34 1094-1099.
86. H Vogelsang, P Ferenci, H Resch, et al. (1995) Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 7 609-614.
87. TM Trebble, SA Wootton, MA Stroud, et al. (2004) Laboratory markers predict bone loss in Crohn's disease: Relationship to blood mononuclear cell function and nutritional status. Aliment Pharmacol Ther 19 1063-1071.
88. MT Abreu, V Kantorovich, EA Vasiliauskas, et al. (2004) Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1, 25-dihydroxyvitamin D and low bone mineral density. Gut 53 1129-1136.
89. KA Tuohy and TI Steinman (2005) Hypercalcemia due to excess 1, 25-dihydroxyvitamin D in Crohn's disease. Am J Kidney Dis 45 e3-e6.
90. SD Krasinski, RM Russell, BC Furie, et al. (1985) The prevalence of vitamin K deficiency in chronic gastrointestinal disorders. Am J Clin Nutr 41 639-643.
91. EJ Schoon, MC Muller, C Vermeer, et al. (2001) Low serum and bone vitamin K status in patients with longstanding Crohn's disease: Another pathogenetic factor of osteoporosis in Crohn's disease? Gut 48 473-477.
92. P Duggan, M.K.M. O'Brien M, Kiely M, et al. (2004) Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 99 2178-2185.
93. SE Fugate and AM Ramsey (2004) Resistance to oral vitamin K for reversal of overanticoagulation during Crohn's disease relapse. J Thromb Thrombolysis 17 219-223.
94. CN Bernstein, LL Seeger, PA Anton, et al. (1996) A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: A pilot study. Aliment Pharmacol Ther 10 777-786.
95. MT Cantorna, Y Zhu, M Froicu and A Wittke (2004) Vitamin D status, 1, 25-dihydroxyvitamin D-3, and the immune system. Am J Clin Nutr 80(Suppl) 1717S-1720S.
96. IJ Griffin, SC Kim, PD Hicks, et al. (2004) Zinc metabolism in adolescents with Crohn's disease. Pediatr Res 56 235-239.
97. KM Hendricks and WA Walker (1988) Zinc deficiency in inflammatory bowel disease. Nutr Rev 46 401-408.
98. GC Sturniolo, L.V. Di Leo V, A Ferronato, et al. (2001) Zinc supplementation tightens “leaky gut” in Crohn's disease. Inflamm Bowel Dis 7 94-98.
99. C Brignola, C Belloli, G De Simone, et al. (1993) Zinc supplementation restores plasma concentrations of zinc and thymulin in patients with Crohn's disease. Aliment Pharmacol Ther 7 275-280.
100. JM Reimund, C Hirth, C Koehl, et al. (2000) Antioxidant and immune status in active Crohn's disease: A possible relationship. Clin Nutr 19 43-48.
101. BJ Geerling, A.D.C. Badart-Smook A, van Deursen C, et al. (2000) Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: Effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 6 77-84.
102. T Rannem, K Ladefoged, E Hylander, et al. (1992) Selenium status in patients with Crohn's disease. Am J Clin Nutr 56 933-937.
103. F Kuroki, T Matsumoto and M Iida (2003) Selenium is depleted in Crohn's disease on enteral nutrition. Dig Dis 21 266-270.
104. L Galland (1988) Magnesium and inflammatory bowel disease. Magnesium 7 78-83.
105. H Bohles, OJ Beifuss, U Brandl, et al. (1988) Urinary factors of kidney stone formation in patients with Crohn's disease. Klin Wochenschr 66 87-91.
106. N McConnell, S Campbell, I Gillanders, et al. (2002) Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 89 835-841.
107. A Ravina, L Slezak, N Mirsky, et al. (1999) Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium. Diabet Med 16 164-167.
108. C Gasche, MC Lomer, I Cavill and G Weiss (2004) Iron, anaemia, and inflammatory bowel diseases. Gut 53 1190-1197.
109. B Oldenburg, JC Koningsberger, B. Van Berge, GP Henegouwen, et al. (2001) Iron and inflammatory bowel disease. Aliment Pharmacol Ther 15 429-438.
110. EN Siguel and RH Lerman (1996) Prevalence of essential fatty acid deficiency in patients with chronic gastrointestinal disorders. Metabolism 45 12-23.
111. JA Vanderhoof, DJ Blackwood, H Mohammadpour and JH Park (1991) Effect of dietary menhaden oil on normal growth and development and on ameliorating mucosal injury in rats. Am J Clin Nutr 54 346-350.
112. DJ Ruthig and KA Meckling-Gill (1999) Both omega-3 and omega-6 fatty acids stimulate wound healing in the rat intestinal epithelial cell line, IEC-6. J Nutr 129 1791-1798.
113. WF Stenson, D Cort, J Rodgers, et al. (1992) Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 116 609-615.
114. YZ Almallah, SW Ewen, A El-Tahir, et al. (2000) Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): The mucosal effect in situ. J Clin Immunol 20 68-76.
115. A Aslan and G Triadafilopoulos (1992) Fish oil fatty acid supplementation in active ulcerative colitis: A double-blind, placebo-controlled, crossover study. Am J Gastroenterol 87 432-437.
116. K Loeschke, B Ueberschaer, A Pietsch, et al. (1996) Omega-3 fatty acids retard early relapse in ulcerative colitis in remission. Dig Dis Sci 41 2087-2094.
117. A Belluzzi, C Brignola, M Campieri, et al. (1996) Effect of an enteric coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334 1557-1560.
118. MF van der Hulst RR, van Kreel BK, von Meyenfeldt, et al. (1993) Glutamine and the preservation of gut integrity. Lancet 341 1363-1365.
119. AK Akobeng, V Miller, J Stanton, et al. (2000) Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr 30 78-84.
120. M Den Hond E, Hiele M, Peeters, et al. (1999) Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr 23 7-11.
121. M Shinozaki, H Saito and T Muto (1997) Excess glutamine exacerbates trinitrobenzenesulfonic acid-induced colitis in rats. Dis Colon Rectum 40(Suppl) S59-S63.
122. AF Burton and FH Anderson (1983) Decreased incorporation of 14C-glucosamine relative to 3H- N -acetyl glucosamine in the intestinal mucosa of patients with inflammatory bowel disease. Am J Gastroenterol 78 19-22.
123. SD Ryder, AH Raouf, N Parker, et al. (1995) Abnormal mucosal glycoprotein synthesis in inflammatory bowel diseases is not related to cigarette smoking. Digestion 56 370-376.
124. S Salvatore, R Heuschkel, S Tomlin, et al. (2000) A pilot study of N -acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease. Aliment Pharmacol Ther 14 1567-1579.
125. R de la Torre B, Hedman M, Befrits, et al. (1998) Blood and tissue dehydroepiandrosterone sulphate levels and their relationship to chronic inflammatory bowel disease. Clin Exp Rheumatol 16 579-582.
126. RH Straub, D Vogl, V Gross, et al. (1998) Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol 93 2197-2202.
127. M Szathmari, B Vasarhelyi, A Treszl, et al. (2002) Association of dehydroepiandrosterone sulfate and testosterone deficiency with bone turnover in men with inflammatory bowel disease. Int J Colorectal Dis 17 63-66.
128. T Andus, F Klebl, G Rogler, et al. (2003) Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: A pilot study. Aliment Pharmacol Ther 17 409-414.
129. FH Klebl, N Bregenzer, G Rogler, et al. (2003) Treatment of pouchitis with dehydroepiandrosterone (DHEA): A case report. Z Gastroenterol 41 1087-1090.
130. S O'Sullivan GC, Kelly P, O'Halloran, et al. (2005) Probiotics: An emerging therapy. Curr Pharm Des 11 3-10.
131. A Tursi, G Brandimarte, GM Giorgetti, et al. (2004) Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10 PI126-PI131.
132. R Bibiloni, RN Fedorak, GW Tannock, et al. (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100 1539-1546.
133. P Gionchetti, F Rizzello, A Venturi, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind placebo controlled trial. Gastroenterology 119 305-309.
134. T Mimura, F Rizzello, U Helwig, et al. (2004) Once-daily high-dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 108-114.
135. B Shen, A Brzezinski, VW Fazio, et al. (2005) Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: Experience in clinical practice. Aliment Pharmacol Ther 22 721-728.
136. MP Gosselink, WR Schouten, LM van Lieshout, et al. (2004) Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 47 876-884.
137. M Schultz, A Timmer, HH Herfarth, et al. (2004) Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 4 5.
138. C Prantera, ML Scribano, G Falasco, et al. (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 51 405-409.
139. V McFarland and P Bernasconi (1993) A review of a novel biotherapeutic agent: Saccharomyces boulardii. Microb Ecol Health Dis 6 157-171.
140. CM Surawicz, LV McFarland, G Elmer and J Chinn (1989) Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 84 1285-1287.
141. CM Surawicz, GW Elmer, P Speelman, et al. (1989) Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii : A prospective study. Gastroenterology 96 981-988.
142. JP Buts, P Bernasconi, JP Vaerman and C Dive (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35 251-256.
143. MJ Machado-Caetano JA, Parames MT, Babo, et al. (1986) Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. Int J Immunopharmacol 8 245-259.
144. M Guslandi, P Giollo and PA Testoni (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15 697-698.
145. K Plein and J Hotz (1993) Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea: A pilot study. Z Gastroenterol 31 129-134.
146. M Guslandi, G Mezzi, M Sorghi and PA Testoni (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45 1462-1464.
147. M Cassone, P Serra, F Mondello, et al. (2003) Outbreak of Saccharomyces boulardii subtype boulardii fungaemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 41 5340-5343.
148. L Galland (2005) Functional foods: Health effects and clinical applications. Encyclopedia of Human Nutrition 2nd ed. London: John Wiley & Sons 360-366.
149. C Hallert, I Bjorck, M Nyman, et al. (2003) Increasing fecal butyrate in ulcerative colitis patients by diet: Controlled pilot study. Inflamm Bowel Dis 9 116-121.
150. DL Seidner, BA Lashner, A Brzezinski, et al. (2005) An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial. Clin Gastroenterol Hepatol 3 358-369.
151. T Bamba, O Kanauchi, A Andoh and Y Fujiyama (2002) A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 17 818-824.
152. O Kanauchi, K Mitsuyama, T Homma, et al. (2003) Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med 12 701-704.
153. H Hanai, O Kanauchi, K Mitsuyama, et al. (2004) Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 13 643-647.
154. E Ben-Ayre E, Goldin E, Wengrower, et al. (2002) Wheat grass juice in the treatment of active distal alternative colitis. Scand J Gastroenterol 37 444-449.
155. E Furrie, S Macfarlane, A Kennedy, et al. (2005) A randomised controlled pilot trial. Synbiotic therapy (Bifidobacterium longum /Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis. Gut 54 242-249.
156. RJ Playford, CE Macdonald and WS Johnson (2000) Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr 72 5-14.
157. Z Khan, C Macdonald, AC Wicks, et al. (2002) Use of the “nutriceutical, ” bovine colostrum, for the treatment of distal colitis: Results from an initial study. Aliment Pharmacol Ther 16 1917-1922.
158. RJ Playford, CE MacDonald, DP Calnan, et al. (2001) Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. Clin Sci (Lond) 100 627-633.
159. OH Kang, JA Kim, YA Choi, et al. (2005) Inhibition of interleukin-8 production in the human colonic epithelial cell line HT-29 by 18 beta-glycyrrhetinic acid. Int J Mol Med 15 981-985.
160. L Langmead, C Dawson, C Hawkins, et al. (2002) Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: An in vitro study. Aliment Pharmacol Ther 16 197-205.
161. WG Dong, SP Liu, HH Zhu, et al. (2004) Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis. World J Gastroenterol 10 606-609.
162. HP Ammon (2002) Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases. Wien Med Wochenschr 152 373-378.
163. I Gupta, A Parihar, P Malhotra, et al. (2001) Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 67 391-395.
164. I Gupta, A Parihar, P Malhotra, et al. (1997) Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 2 37-43.
165. H Gerhardt, F Seifert, P Buvari, et al. (2001) Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 39 11-17.
166. L Langmead, RJ Makins and DS Rampton (2004) Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther 19 521-527.
167. L Langmead, RM Feakins, S Goldthorpe, et al. (2004) Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 19 739-747.
168. M Robinson (1998) Medical therapy of inflammatory bowel disease for the 21st century. Eur J Surg Suppl (582) 90-98.
169. T von Wietersheim J, Kohler and H Feiereis (1992) Relapse-precipitating life events and feelings in patients with inflammatory bowel disease. Psychother Psychosom 58 103-112.
170. CS North, DH Alpers, JE Helzer, et al. (1991) Do life events or depression exacerbate inflammatory bowel disease? A prospective study. Ann Intern Med 114 381-386.
171. RG. Maunder and MJ Esplen (2001) Supportive-expressive group psychotherapy for persons with inflammatory bowel disease. Can J Psychiatry 46 622-626.
172. G Jantschek, M Zeitz, M Pritsch, et al. (1998) Effect of psychotherapy on the course of Crohn's disease: Results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn's Disease. Scand J Gastroenterol 33 1289-1296.
173. SP Schwarz and EB Blanchard (1991) Evaluation of a psychological treatment for inflammatory bowel disease. Behav Res Ther 29 167-177.
174. A Robinson, DG Thompson, W Wilin, et al. (2001) Guided self-management and patient-directed follow-up of ulcerative colitis: A randomized trial. Lancet 358 976-981.
175. C Yang and H Yan (1999) Observation of the efficacy of acupuncture and moxibustion in 62 cases of chronic colitis. J Tradit Chin Med 19 111-114.
176. X Zhang (1998) Twenty-three cases of chronic nonspecific ulcerative colitis treated by acupuncture and moxibustion. J Tradit Chin Med 18 188-191.
177. H Wu, H Chen, X Hua, et al. (1997) Clinical therapeutic effect of drug-separated moxibustion on chronic diarrhea and its immunologic mechanisms. J Tradit Chin Med 17 253-258.
178. Y Li, G Tougas, SG Chiverton and RH Hunt (1992) The effect of acupuncture on gastrointestinal function and disorders. Am J Gastroenterol 87 1372-1381.
179. L Sutherland, J Singlewton, J Sessions, et al. (1991) Double-blind placebo-controlled trial of metronidazole in Crohn's disease. Gut 32 1071-1075.
180. UM Turunen, MA Farkkila, K Hakala, et al. (1998) Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled study. Gastroenterology 115 1072-1078.
181. LV McFarland, CM Surawicz, RN Greenberg, et al. (1994) A randomized, placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271 1913-1918.
182. K Rajnarayana, MS Reddy, J Vidyasagar, et al. (2004) Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 54 109-113.
183. CH Chuang, BS Sheu, AH Huang, et al. (2002) Vitamins C and E supplements to lansoprazole-amoxacillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-sensitive Helicobacter pylori infection. Helicobacter 7 310-316.
184. AN Lee and VP Wirth (2004) Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol 140 723-777.
185. DT Chu, WL Wong, GM Mavligit, et al. (1988) Immunotherapy with Chinese medicinal herbs: II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol 25 125-129.
186. E Ernst (2002) St. John's Wort supplements endanger the success of organ transplantation. Arch Surgery 137 316-319.
187. VJ Wacher, S Wong and HT Wong (2002) Peppermint oil enhances cyclosporine bioavailability in rats: Comparison with d -alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and keotconazole. J Pharm Sci 91 77-90.
188. AM Homan van der Heide JJ, Bilo HJ, Tegzess, AJ Donker, et al. (1990) The effects of dietary supplementation with fish oil on renal function in cyclosporine-treated renal transplant recipients. Transplantation 49 523-527.
189. S Badalamenti, F Salerno, E Lorenzano, et al. (1995) Renal effects of dietary supplementation with fish oil in cyclosporine-treated liver transplant recipients. Hepatology 22 1671-1695.
190. P de Lorgeril M, Boissonnat P, Salen, et al. (1994) The beneficial effect of dietary antioxidant supplementation on platelet aggregation and cyclosporine treatment in heart transplant patients. Transplantation 58 193-195.
191. D Agnusdei and L Bufalino (1997) Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int 61(Suppl 1) S23-S27.
192. WJ Sandborn (2005) New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 5 10-18.
193. MA Parsi, JP Achkar, S Richardson, et al. (2002) Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123 707-713.